Treatment options for acute decompensated heart failure.

Am J Health Syst Pharm

University of Illinois at Chicago, 840 S. Wood Street M/C 715, Chicago, IL 60612, USA.

Published: August 2003

The benefits of nesiritide for the treatment of acute decompensated heart failure (ADHF) are discussed. In order to understand the goals of ADHF therapy, it is important to recognize the complex interplay between hemodynamic and neurohormonal abnormalities in patients suffering from heart failure. Goals of therapy include improvement in hemodynamic parameters, relief of symptoms, and minimization of adverse effects. Until recently, therapy with diuretics, positive inotropes, and intravenous vasodilators was the standard of care for treating ADHF. Nesiritide is the newest agent available for treating ADHF and may offer several benefits over standard of care therapy. It is important to remember that therapy for ADHF should not replace chronic oral heart failure therapy, nor should focus on prevention of ADHF episodes be lost.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/60.suppl_4.S7DOI Listing

Publication Analysis

Top Keywords

heart failure
16
acute decompensated
8
decompensated heart
8
standard care
8
treating adhf
8
adhf
6
therapy
6
treatment options
4
options acute
4
heart
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!